GW Pharma slumped today after the maker of cannabis medicines revealed some disappointing results from a recent Sativex study.
The company reported that results from Phase III studies into the cannabis-based medicine Sativex failed to reach statistical significance.
The trial was supposed to identify whether Sativex could be used to treat the relief of spasticity in people with Multiple Sclerosis.
"Analysis of the Intention to Treat population - incorporating all patients regardless of whether they complied with protocol - was in favour of Sativex but not to a degree that reached statistical significance," said GW Pharma.
The group said the study was one of a number of Phase III studies which are currently taking place to support approval of Sativex across Europe in a range of target indications.
Source: Yahoo Finance Copyright © 2006 ShareCast. All rights reserved.